Clinical Trial Update: Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of ALRN-6924, a dual MDM2/MDMX inhibitor, in pediatric cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Leukemia
• Lymphoma
• Solid Tumor

Drugs mentioned

• ALRN-6924 (MDM2/MDMX dual inhibitor)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Leukemia, Brain Tumor | Phase 1 | Status: COMPLETED